Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis | Completed | Systemic Scleroderma, Severe Systemic Sclerosis | Drug, Drug, Drug, Radiation, Procedure, Procedure, Procedure, Other, Other, Procedure - fludarabine phosphate, Mycophenolic Acid, tacrolimus, total-body irradiation, bone marrow transplantation, reduced intensity allogeneic hematopoietic stem cell transplantation, quality-of-life assessment, laboratory biomarker analysis, flow cytometry, biopsy | Fred Hutchinson Cancer Research Center, National Institute of Allergy and Infectious Diseases (NIAID), Other, NIH | N/A - 70 Years | Phase 1/Phase 2 | Interventional | The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis. In an allogeneic bone marrow transplant procedure, bone marrow is taken from a healthy donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who is a complete tissue type match. Participants will receive the chemotherapy and low dose radiation conditioning regimen consisting of the following: Fludarabine will be given intravenously for 5 days. Cyclophosphamide will be given intravenously on the first and second day. After completing the fludarabine and cyclophosphamide, patients will receive a single low dose of total body irradiation. The next day, patients will receive the allogeneic bone marrow transplant. On the third and fourth day after the transplant, patients will receive high dose intravenous cyclophosphamide. This is given to help prevent two complications: (1) graft rejection, which occurs when the body's immune system rejects the donor bone marrow, and (2) graft-versus-host disease (GVHD), which is when the donor immune cells attack the patient's normal tissues. On the fifth day after the transplant, patients will start receiving two additional medications: tacrolimus and mycophenolic acid (MPA, Myfortic), to help prevent GVHD. Patients will receive mycophenolic acid for about 5 weeks and tacrolimus for about 6 months. Also beginning on the fifth day after the transplant, patients will receive daily injections of a growth factor called granulocyte-colony stimulating factor (G-CSF), which is a protein that increases the white blood cell count; G-CSF will be continued until the patient's white blood cell count has returned to normal levels. Patients will remain closely monitored either in the outpatient clinic setting or in the hospital for approximately 2-3 months after the transplant, but possibly longer if there are complications. Follow-up study visits will occur at 6 months and then at 1, 2, 3, 4, and 5 years after the transplant. Study researchers will keep track of the patient's medical condition after leaving the transplant center by phone calls or mailings to patients and their doctors once a year for the rest of the study participants' lives. | ||
Clinicaltrials.gov | Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | Multiple Myeloma and Plasma Cell Neoplasm | Drug, Genetic, Genetic, Genetic, Other, Other, Procedure - everolimus, DNA analysis, protein analysis, western blotting, flow cytometry, laboratory biomarker analysis, biopsy | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with relapsed or refractory multiple myeloma. | ||
|
Clinicaltrials.gov | IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor | Completed | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific | Biological, Other, Other - cixutumumab, pharmacological study, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 1 Year - 21 Years | Phase 1 | Interventional | This phase I clinical trial is studying the side effects and best dose of IMC-A12 in treating young patients with relapsed or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor or other solid tumors. Monoclonal antibodies, such as IMC-A12, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. | ||
|
Clinicaltrials.gov | Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer | Completed | Pancreatic Cancer | Biological, Drug, Drug, Drug, Other, Other, Procedure, Procedure, Procedure, Radiation - bevacizumab, fluorouracil, gemcitabine hydrochloride, oxaliplatin, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, endoscopic biopsy, laparoscopy, radiation therapy | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as gemcitabine, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving bevacizumab together with combination chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: The phase II trial is studying the side effects and how well giving bevacizumab together with gemcitabine, oxaliplatin, fluorouracil, and radiation therapy works in treating patients undergoing surgery for locally advanced pancreatic cancer. | ||
|
Clinicaltrials.gov | F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer | Completed | Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | Radiation, Radiation, Procedure, Procedure, Procedure, Other - F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography, positron emission tomography, computed tomography, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | Female | 18 Years - N/A | Phase 2 | Interventional | This phase II trial is studying how well F-18 16 alpha-fluoroestradiol (FES) imaging works in predicting response to first-line hormone therapy in women with hormone receptor-positive metastatic breast cancer. Diagnostic procedures, such as FES imaging, may help predict how well patients will respond to hormone therapy and may help plan the best treatment. | |
|
Clinicaltrials.gov | Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery | Completed | Head and Neck Cancer | Drug, Genetic, Genetic, Other, Other, Other, Other, Procedure, Procedure - erlotinib hydrochloride, protein analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, neoadjuvant therapy, therapeutic conventional surgery | Wake Forest University Health Sciences, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Early Phase 1 | Interventional | RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment with erlotinib. PURPOSE: This clinical trial is studying how well erlotinib works when given before surgery in treating patients with head and neck cancer that can be removed by surgery. | ||
|
Clinicaltrials.gov | PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer | Terminated | Kidney Cancer | Biological, Drug, Genetic, Genetic, Genetic, Other, Other, Other - PEG-interferon alfa-2b, Sorafenib, gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, laboratory biomarker analysis | Thomas Olencki, Schering-Plough, Other, Industry | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of kidney cancer by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b together with sorafenib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b and sorafenib in treating patients with unresectable or metastatic kidney cancer. | ||
|
Clinicaltrials.gov | Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer | Unknown status | Head and Neck Cancer | Biological, Drug, Other, Other, Other - Ad5F35-LMP1/LMP2-transduced autologous dendritic cells, celecoxib, flow cytometry, immunoenzyme technique, laboratory biomarker analysis | National Cancer Centre, Singapore, Other | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving vaccine therapy together with celecoxib works in treating patients with metastatic nasopharyngeal cancer. | ||
|
Clinicaltrials.gov | Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia | Terminated | Oral Leukoplakia | Drug, Drug, Other - aminolevulinic acid hydrochloride, photodynamic therapy, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - N/A | Phase 1 | Interventional | This phase I trial studies the side effects and best dose of photodynamic therapy using aminolevulinic acid in treating patients with oral leukoplakia. Photodynamic therapy uses a drug, such as aminolevulinic acid, that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using aminolevulinic acid may be effective against oral leukoplakia. | ||
|
Clinicaltrials.gov | Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma | Completed | Melanoma (Skin) | Biological, Other, Other, Other, Other, Procedure, Procedure, Procedure - sargramostim, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, biopsy, cryosurgery, radiofrequency ablation | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: Radiofrequency therapy and radiofrequency ablation use a high-frequency electric current to kill tumor cells. Radiofrequency therapy can also cause the body to produce heat-shock proteins which may help kill more tumor cells. Cryotherapy kills tumor cells by freezing them. It is not yet known whether heat-shock proteins caused by radiofrequency therapy given together with radiofrequency ablation or cryotherapy is more effective in treating stage IV melanoma than radiofrequency therapy-induced heat-shock proteins alone. PURPOSE: This randomized clinical trial is studying the side effects of radiofrequency therapy-induced endogenous heat-shock proteins when given alone or together with radiofrequency ablation or cryotherapy in treating patients with stage IV melanoma. | ||
|
Clinicaltrials.gov | Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia | Completed | Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Drug, Other - dasatinib, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - N/A | Phase 2 | Interventional | This phase II trial is studying how well dasatinib works in treating patients with unresectable or metastatic squamous cell skin cancer or RAI Stage 0-I chronic lymphocytic leukemia. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. | ||
|
Clinicaltrials.gov | Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma | Unknown status | Lymphoma, Small Intestine Cancer | Biological, Drug, Drug, Drug, Drug, Genetic, Other, Other, Other - alemtuzumab, cyclophosphamide, doxorubicin hydrochloride, prednisolone, vincristine sulfate, polymerase chain reaction, flow cytometry, laboratory biomarker analysis, pharmacological study | Cancer Research UK, Other | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from growing. Giving alemtuzumab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with stage I , stage II , stage III, or stage IV peripheral T-cell lymphoma. | ||
|
Clinicaltrials.gov | Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer | Completed | Unspecified Adult Solid Tumor, Protocol Specific | Drug, Drug, Other - celecoxib, cyclophosphamide, laboratory biomarker analysis | City of Hope Medical Center, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with celecoxib may help kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib when given together with cyclophosphamide in treating patients with advanced cancer. | ||
|
Clinicaltrials.gov | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | Completed | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | Biological, Biological, Drug, Other, Other, Other, Other, Other, Other - pertuzumab, cetuximab, irinotecan hydrochloride, immunohistochemistry staining method, fluorescence in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - N/A | Phase 1/Phase 2 | Interventional | Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving pertuzumab together with cetuximab may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of pertuzumab when given together with cetuximab and to see how well they work in treating patients with previously treated locally advanced or metastatic colorectal cancer | ||
|
Clinicaltrials.gov | DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements | Completed | Colorectal Cancer | Dietary Supplement, Genetic, Genetic, Genetic, Genetic, Genetic, Other, Other, Other, Procedure, Procedure - cholecalciferol, polymerase chain reaction, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy, immunoscintigraphy | Roswell Park Cancer Institute, Other | 18 Years - 120 Years | N/A | Interventional | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This clinical trial is studying changes in DNA that affect vitamin D metabolism in patients with colorectal cancer receiving vitamin D supplements. | ||
|
Clinicaltrials.gov | Natural Killer Cells in Older Patients With Acute Myeloid Leukemia | Completed | Leukemia | Drug, Other - cytarabine, laboratory biomarker analysis | Institut Paoli-Calmettes, Other | 65 Years - N/A | N/A | Interventional | RATIONALE: Studying natural killer cells in samples of blood from patients with cancer may help doctors find out how these cells are effected by chemotherapy. PURPOSE: This clinical trial is studying natural killer cells in older patients with acute myeloid leukemia. | ||
|
Clinicaltrials.gov | Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | Terminated | Adenocarcinoma of the Prostate, Stage IV Prostate Cancer | Drug, Drug, Drug, Other - cediranib maleate, docetaxel, prednisone, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | Male | 18 Years - N/A | Phase 2 | Interventional | This randomized phase II trial is studying how well giving docetaxel and prednisone together with or without cediranib works in treating patients with metastatic prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving docetaxel together with prednisone, with or without cediranib, may kill more tumor cells. | |
|
Clinicaltrials.gov | Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer | Completed | Breast Cancer | Genetic, Other, Other, Procedure - polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - N/A | Observational | RATIONALE: Studying changes in breast density and blood hormone levels in women receiving anastrozole or exemestane for breast cancer may help doctors learn more about the long-term effects of treatment and may help the study of breast cancer in the future. PURPOSE: This clinical trial is studying changes in breast density and blood hormone levels in postmenopausal women receiving anastrozole or exemestane for breast cancer. | ||
|
Clinicaltrials.gov | Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | Terminated | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | Drug, Other, Other, Other, Other - sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Bayer, Other, NIH, Industry | Female | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in at least the second remission. | |
|
Clinicaltrials.gov | Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer | Terminated | Lung Cancer | Drug, Drug, Drug, Other - celecoxib, Docetaxel, pemetrexed disodium, laboratory biomarker analysis | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes need for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving celecoxib together with docetaxel or pemetrexed may kill more tumor cells. PURPOSE: This phase II trial is studying how well celecoxib given together with docetaxel or pemetrexed works in treating patients with advanced or recurrent non-small cell lung cancer. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
